About OncoImmunity
OncoImmunity is a company based in Oslo (Norway) founded in 2014 was acquired by NEC in July 2019. OncoImmunity has raised $7.37 million across 6 funding rounds from investors including NEC, European Union and EIC Fund. The company has 16 employees as of December 31, 2022. OncoImmunity offers products and services including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations. OncoImmunity operates in a competitive market with competitors including Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
- Headquarter Oslo, Norway
- Employees 16 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nec Oncoimmunity As
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoImmunity
OncoImmunity offers a comprehensive portfolio of products and services, including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations.
AI tool for immune profiling in cancer vaccine research
Predicts epitopes for infectious disease vaccines
Simulates biological processes for therapy development
People of OncoImmunity
Unlock access to complete
Unlock access to complete
Funding Insights of OncoImmunity
OncoImmunity has successfully raised a total of $7.37M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $57.8 thousand completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoImmunity
OncoImmunity has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NEC, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Cloud-based IT and networking solutions are provided globally.
|
Locked | Locked | Locked |
Investor details for OncoImmunity
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoImmunity
Investment portfolio details for OncoImmunity
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OncoImmunity
Detailed financials for OncoImmunity
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncoimmunity Comparisons
Peer comparison for OncoImmunity
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoImmunity
OncoImmunity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI-driven drug discovery platform for the treatment of cancer
|
Detailed competitors of OncoImmunity
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncoimmunity
Complete news archive for OncoImmunity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoImmunity
OncoImmunity was founded in 2014 and raised its 1st funding round 3 years after it was founded.
OncoImmunity is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
OncoImmunity is a funded company, having raised a total of $7.37M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at OncoImmunity is 16.
Annual revenue of OncoImmunity is $1.34M as on Mar 31, 2022.
OncoImmunity was established in 2014 in Oslo, Norway, as a bioinformatics firm. Machine-learning tools are utilized to predict immunogenic neoantigens, addressing gaps in personalized cancer immunotherapy. Patient selection for treatments is facilitated, and targets for vaccines and cell therapies are identified within actionable timelines. Operations focus on clinical applications in oncology, with incubation support from the Oslo Cancer Cluster.
OncoImmunity's top competitors include Owkin, Formation Bio and XtalPi.
OncoImmunity offers NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations.
OncoImmunity has 3 investors. Key investors include NEC, European Union, and EIC Fund.